Cytokinetics

Cytokinetics Inventory

The Inventory of Cytokinetics (CYTK) as of Oct 12, 2026 is -11.94 M USD. In the previous year, Inventory was -147,000.00 USD — a change of 8,025.17% (lower).

Inventory

-11.94 MUSD

YoY

8,025.17%

Last updated:

Inventory of Cytokinetics is 2023 -11.94 M USD. Inventory of Cytokinetics was 2022 -147,000.00 USD. It decreases by 8,025.17% lower compared to the previous year.

The Cytokinetics Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2015
0.00 USD
Jan 1, 2016
0.00 USD
Jan 1, 2017
1.00 USD
Jan 1, 2018
-6.79 M USD
Jan 1, 2020
-4.42 M USD
Jan 1, 2021
-51.82 M USD
Jan 1, 2022
-147,000.00 USD
Jan 1, 2023
-11.94 M USD
The Cytokinetics Inventory history
YEARInventoryYoY
-11.94 MUSD+8,025.17%
-147,000.00USD-99.72%
-51.82 MUSD+1,072.38%
-4.42 MUSD-34.86%
-6.79 MUSD-678.50 M%
1.00USD—
0.00USD—
0.00USD-100.00%
1.00USD—
Access this data via the Eulerpool API
Get Free API Key

Cytokinetics Stock analysis

What does Cytokinetics do? Cytokinetics Inc. is a biotechnology company that was founded in 1998 and is headquartered in South San Francisco, California. The company focuses on developing novel therapies for diseases of the nervous system, cardiovascular system, and muscles. Cytokinetics develops its drugs by identifying proteins and molecules that have potential for treating diseases. The company's business model is based on the development of therapies that target the improvement of muscle strength and function. Cytokinetics is known for its innovative drug classes such as myosin inhibitors and activators, as well as its novel drug CK-274. The company offers various products aimed at improving muscle strength and function, including CK-274, a myosin inhibitor currently in phase III development for the treatment of hypertrophic cardiomyopathy. Cytokinetics is also the developer of Omecamtiv Mecarbil, a myosin activator for the treatment of heart failure, and SMN2 splicing modulators for improving SMN protein synthesis in patients with spinal muscular atrophy. The company has established partnerships with leading pharmaceutical companies for the further development and commercialization of its drugs. With its innovative therapies and industry expertise, Cytokinetics has become one of the leading biotechnology companies in the United States focused on improving muscle strength and function. Cytokinetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cytokinetics stock

Inventory of Cytokinetics is -11.94 M USD in 2023.

Inventory of Cytokinetics changed from -147,000.00 USD to -11.94 M USD, representing a 8,025.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Inventory Cytokinetics since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Cytokinetics historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Cytokinetics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Cytokinetics